New therapeutic agents targeting the epidermal growth factor receptorBASELGA, José.Journal of clinical oncology. 2000, Vol 18, Num 21, pp 54s-59s, issn 0732-183X, SUPArticle

Frontiers in cancer research : Targeting tyrosine kinases in cancer: The second waveBASELGA, Jose.Science (Washington, D.C.). 2006, Vol 312, Num 5777, pp 1175-1178, issn 0036-8075, 4 p.Article

The epidermal growth factor receptor pathway : A model for targeted therapy : Predictive preclinical models of human cancer: Mouse models get another chanceSCALTRITI, Maurizio; BASELGA, José.Clinical cancer research. 2006, Vol 12, Num 18, pp 5268-5272, issn 1078-0432, 5 p.Article

Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trialsBASELGA, José.Oncology. 2001, Vol 61, pp 14-21, issn 0030-2414, SUP2Conference Paper

Impact of Genomics on Personalized Cancer MedicineARTEAGA, Carlos L; BASELGA, José.Clinical cancer research (Print). 2012, Vol 18, Num 3, pp 612-618, issn 1078-0432, 7 p.Article

Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer : Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical InvestigationBARDIA, Aditya; BASELGA, José.Clinical cancer research (Print). 2013, Vol 19, Num 23, pp 6360-6370, issn 1078-0432, 11 p.Article

New treatment concepts in breast cancerBASELGA, José; BODY, Jean-Jacques.Seminars in oncology. 2004, Vol 31, Num 5, issn 0093-7754, 93 p., SUP10Serial Issue

Phosphoinositide 3-Kinase Mutations in Breast Cancer: A Good Activating Mutation?DI COSIMO, Serena; BASELGA, José.Clinical cancer research (Print). 2009, Vol 15, Num 16, pp 5017-5019, issn 1078-0432, 3 p.Article

Critical update and emerging trends in epidermal growth factor receptor targeting in cancerBASELGA, José; ARTEAGA, Carlos L.Journal of clinical oncology. 2005, Vol 23, Num 11, pp 2445-2459, issn 0732-183X, 15 p.Article

Targeting the epidermal growth factor receptor : A clinical realityBASELGA, José.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 41s-44s, issn 0732-183X, SUPConference Paper

Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practicesARTEAGA, Carlos L; BASELGA, Jose.Clinical cancer research. 2003, Vol 9, Num 5, pp 1579-1589, issn 1078-0432, 11 p.Article

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerMENDELSOHN, John; BASELGA, Jose.Journal of clinical oncology. 2003, Vol 21, Num 14, pp 2787-2799, issn 0732-183X, 13 p.Article

Molecular approach to breast cancer treatmentYARDEN, Yosef; BASELGA, José; MILES, David et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 6-13, issn 0093-7754, 8 p., SUP10Article

ZD1839 ('Iressa')^1,2 as an anticancer agentBASELGA, José; AVERBUCH, Steven D.Drugs (Basel). 2000, Vol 60, pp 33-40, issn 0012-6667, SUP1Article

Current and planned clinical trials with trastuzumab (herceptin)BASELGA, José.Seminars in oncology. 2000, Vol 27, Num 5, pp 27-32, issn 0093-7754, SUP9Conference Paper

Patient management issues in metastatic bone disease : IbandronateCAMERON, David.Seminars in oncology. 2004, Vol 31, Num 5, pp 79-82, issn 0093-7754, 4 p., SUP10Article

Monoclonal antibodies directed at growth factor receptorsBASELGA, José.Annals of oncology. 2000, Vol 11, pp 187-190, issn 0923-7534, SUP3Conference Paper

Clinical trials of single-agent trastuzumab (herceptin)BASELGA, José.Seminars in oncology. 2000, Vol 27, Num 5, pp 20-26, issn 0093-7754, SUP9Conference Paper

Thérapies ciblées et cancer colorectal = Targeting EGFR and VEGF in colorectal cancer patientsSPANO, Jean-Philippe; MILANO, Gérard; BASELGA, José et al.Bulletin du cancer. 2005, Vol 92, issn 0007-4551, 43 p., NSSerial Issue

Epithelial growth factor receptor interacting agentsBASELGA, Jose; ALBANELL, Joan.Hematology/oncology clinics of North America. 2002, Vol 16, Num 5, issn 0889-8588, v, 1041-1063 [24 p.]Article

The EGF receptor family as targets for cancer therapyMENDELSOHN, John; BASELGA, Jose.Oncogene (Basingstoke). 2000, Vol 19, Num 56, pp 6550-6565, issn 0950-9232Article

Future options with trastuzumab for primary systemic and adjuvant therapyBASELGA, José; GIANNI, Luca; GEYER, Charles et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 51-57, issn 0093-7754, 7 p., SUP10Article

Perspectives on the future of bisphosphonate use in breast cancer patients : IbandronateCLEMONS, Mark; REA, Daniel.Seminars in oncology. 2004, Vol 31, Num 5, pp 87-91, issn 0093-7754, 5 p., SUP10Article

Outils pharmacologiques du ciblage du récepteur du facteur de croissance épidermique et du VEGF = Pharmacological skills for targeting EGFR and VEGFMILANO, Gérard.Bulletin du cancer. 2005, Vol 92, pp S17-S20, issn 0007-4551, NSArticle

Bisphosphonates in the treatment of skeletal metastases : IbandronateCONTE, Pierfranco; COLEMAN, Robert.Seminars in oncology. 2004, Vol 31, Num 5, pp 59-63, issn 0093-7754, 5 p., SUP10Article